Lamivudine – still actual therapeutic option for protection of HBV infection reactivation and vertical transmission Waldemar Halota, Małgorzata Pawłowska Medical Science Review - Hepatologia 2010; 10 58-61 aaICID: 911683
Article type: Review article
IC™ Value: 3.34
Abstract provided by Publisher
Immunosuppressant therapy induced risk of HBV reactivation among selected group of patients. It concerns especially patients with anti-HBc serum presence. Among them occult B hepatitis are very frequent. Risk of reactivation needs chemoprophylaxis. Lamivudine is the first line therapy, because of limited period of treatment. Antiviral therapy with Lamivudine during the third trimester of pregnancy in high – risk women with HBV infection reduces viral load in the mother and may decrease the risk of perinatal transmission.